Learn More
e19562 Background: 5-FU is used in the treatment of 275,000 U.S. cancer patients each year. Patient variability in 5-FU metabolism causes many patients to be under dosed with 5-FU while other(More)
PURPOSE Several groups have reported that the combination of doxorubicin plus paclitaxel given as a 3-hour intravenous (IV) infusion for up to eight cycles produces a high response rate (> 80%) and(More)
PURPOSE Although hormonal therapy represents standard therapy for metastatic hormone-sensitive disease, many patients receive initial chemotherapy because of the location, bulk, or aggressiveness of(More)
OBJECTIVE The objective of this multicenter phase III trial was to study the impact on time to treatment failure (TTF) and survival of cyclophosphamide, Adriamycin, and 5-fluorouracil (CAF) versus(More)
  • 1